Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The prognoses of recurrent/metastatic head and neck epithelial tumors after first-line
platinum-based chemotherapy is poor. The efficacy of second-line chemotherapy for those
patients that cannot be re-irradiated or re-operated is limited according to NCCN guideline
and other published data. This study was designed to evaluate the efficacy and safety of
endostatin combined with second-line chemotherapy for patients of recurrent/metastatic head
and neck epithelial tumors that cannot be re-irradiated or re-operated after fist-line
platinum-based chemotherapy.